{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:46:43Z","timestamp":1787838403087,"version":"build-2784847793"},"reference-count":50,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T00:00:00Z","timestamp":1665187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>The prevention of joint deformity is among the most important treatment goals of psoriatic arthritis. Some biologics disease-modifying antirheumatic drugs (bDMARDs) have been demonstrated to be effective for both the skin and joints, as well as for slowing radiographic progression. However, there has been a lack of direct comparisons of bDMARDs. To evaluate the comparative effects of bDMARDs in preventing radiographic progression in psoriatic arthritis, we conducted a systematic review and network meta-analysis. On March 7 2022, a search for relevant randomized trials was conducted on MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials. Our outcomes included radiographic non-progression, a mean change in the total radiographic score, and adverse events leading to discontinuation (DAE) at week 24. We included 11 trials on 10 bDMARDs, involving 4010 participants. Most bDMARDs were more effective than placebos in achieving radiographic non-progression, including adalimumab (odds ratio (OR) 4.7, 95% confidence interval (CI) 2.66\u20138.29), etanercept (OR 4.19, 95% CI 1.65\u201310.61), certolizumab pegol (OR 2.83, 95% CI 1.55\u20135.2), secukinumab 300 mg (OR 2.63, CI 1.62\u20134.27), infliximab (OR 2.54, CI 1.13\u20135.69), ixekizumab (OR 2.22, 95% CI 1.06\u20134.65), golimumab (OR 2.21, 95% CI 1.24\u20133.93), and abatacept (OR 1.54, 95% CI 1.03\u20132.28). A significant reduction in the total radiographic score was found in infliximab (standardized mean difference (SMD) \u22120.59, 95% CI \u22120.87, \u22120.3), etanercept (SMD \u22120.51, 95% CI \u22120.78, \u22120.23), adalimumab (SMD \u22120.45, 95% CI \u22120.64, \u22120.26), ixekizumab (SMD \u22120.37, 95% CI \u22120.62, \u22120.12), secukinumab 300 mg (SMD \u22120.33, 95% CI \u22120.50, \u22120.15), golimumab (SMD \u22120.33, 95% CI \u22120.58, \u22120.09), secukinumab 150 mg (SMD \u22120.25, 95% CI \u22120.43, \u22120.07), certolizumab pegol (SMD \u22120.23, 95% CI \u22120.44, \u22120.03), and ustekinumab (SMD \u22120.19, 95% CI \u22120.35, \u22120.33). No significant differences in DAE were detected between bDMARDs. In conclusion, anti-tumor necrosis factor agents (adalimumab, infliximab, and etanercept) may be preferred for treating psoriatic arthritis for their superiority in preventing radiographic progression.<\/jats:p>","DOI":"10.3390\/pharmaceutics14102140","type":"journal-article","created":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T01:21:07Z","timestamp":1665364867000},"page":"2140","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Biologic Disease-Modifying Antirheumatic Drugs for Preventing Radiographic Progression in Psoriatic Arthritis: A Systematic Review and Network Meta-Analysis"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1960-5072","authenticated-orcid":false,"given":"Szu-Hsuan","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Chang Gung Memorial Hospital, Linkou, Taoyuan 33305, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4471-8711","authenticated-orcid":false,"given":"Chia-Ling","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Chang Gung Memorial Hospital, Linkou, Taoyuan 33305, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1028-5030","authenticated-orcid":false,"given":"Tzu-Yu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Applied Cosmetology, Lee-Ming Institute of Technology, New Taipei 24346, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8833-6155","authenticated-orcid":false,"given":"Chung-Han","family":"Yang","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Linkou, Taoyuan 33305, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5699-0283","authenticated-orcid":false,"given":"Ching-Chi","family":"Chi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Chang Gung Memorial Hospital, Linkou, Taoyuan 33305, Taiwan"},{"name":"School of Medicine, College of Medicine, Chang Gung University, Taoyuan 33302, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","article-title":"Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies","volume":"80","author":"Alinaghi","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jaad.2005.03.046","article-title":"Epidemiology of psoriatic arthritis in the population of the United States","volume":"53","author":"Gelfand","year":"2005","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/ds.ds_53_20","article-title":"Correlation of clinical diagnosis of dactylitis by the dermatologist and ultrasonographic diagnosis by the rheumatologist in patients with psoriasis arthritis: Experience of a single clinic","volume":"39","author":"Lo","year":"2021","journal-title":"Dermatol. Sin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4103\/ds.ds_55_20","article-title":"Risk of chronic kidney disease and end-stage renal disease in patients with psoriasis: A systematic review and meta-analysis of cohort studies","volume":"39","author":"Yang","year":"2021","journal-title":"Dermatol. Sin."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"65","DOI":"10.7861\/clinmedicine.17-1-65","article-title":"Psoriatic arthritis: State of the art review","volume":"17","author":"Coates","year":"2017","journal-title":"Clin. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"28","DOI":"10.5435\/00124635-201201000-00004","article-title":"Psoriatic arthritis","volume":"20","author":"Day","year":"2012","journal-title":"J. Am. Acad. Orthop. Surg."},{"key":"ref_7","first-page":"ii61","article-title":"Psoriatic arthritis imaging: A review of scoring methods","volume":"64","author":"Sharp","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jfma.2020.08.026","article-title":"Recommendations for psoriatic arthritis management: A joint position paper of the Taiwan Rheumatology Association and the Taiwanese Association for Psoriasis and Skin Immunology","volume":"120","author":"Tsai","year":"2021","journal-title":"J. Formos. Med Assoc."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Coates, L.C., Navarro-Coy, N., Brown, S.R., Brown, S., McParland, L., Collier, H., Skinner, E., Law, J., Moverley, A., and Pavitt, S. (2013). The TICOPA protocol (TIght COntrol of Psoriatic Arthritis): A randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis. BMC Musculoskelet. Disord., 14.","DOI":"10.1186\/1471-2474-14-101"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1093\/rheumatology\/keg384","article-title":"A prospective, clinical and radiological study of early psoriatic arthritis: An early synovitis clinic experience","volume":"42","author":"Kane","year":"2003","journal-title":"Rheumatology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/1529-0131(199806)41:6<1103::AID-ART18>3.0.CO;2-N","article-title":"Mortality studies in psoriatic arthritis: Results from a single outpatient center. II. Prognostic indicators for death","volume":"41","author":"Gladman","year":"1998","journal-title":"Arthritis Rheum."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jaad.2008.02.040","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: Overview and guidelines of care for treatment with an emphasis on the biologics","volume":"58","author":"Gottlieb","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4103\/1027-8117.349030","article-title":"Recommendations on use of systemic treatments for immune-mediated dermatologic disorders in patients with confirmed COVID-19 infection: A rapid review","volume":"40","author":"Yu","year":"2022","journal-title":"Dermatol. Sin."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","article-title":"Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Mease","year":"2005","journal-title":"Arthritis Rheum."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/art.22379","article-title":"Adalimumab for long-term treatment of psoriatic arthritis: Forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial","volume":"56","author":"Gladman","year":"2007","journal-title":"Arthritis Rheum."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","article-title":"Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression","volume":"50","author":"Mease","year":"2004","journal-title":"Arthritis Rheum."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1002\/art.22805","article-title":"Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2","volume":"56","author":"Kavanaugh","year":"2007","journal-title":"Arthritis Rheum."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1136\/ard.2005.045658","article-title":"The infliximab multinational psoriatic arthritis controlled trial (IMPACT): Results of radiographic analyses after 1 year","volume":"65","author":"Kavanaugh","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1136\/annrheumdis-2013-203697","article-title":"Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: Results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol","volume":"73","author":"Fleischmann","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1002\/art.34436","article-title":"Golimumab in psoriatic arthritis: One-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial","volume":"64","author":"Kavanaugh","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1093\/rheumatology\/kez420","article-title":"Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5","volume":"59","author":"Mease","year":"2020","journal-title":"Rheumatology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1136\/annrheumdis-2013-204741","article-title":"Ustekinumab, an anti-IL-12\/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: Results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1136\/annrheumdis-2016-210724","article-title":"Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis","volume":"76","author":"Mease","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","article-title":"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): A double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Mease","year":"2020","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","article-title":"Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: Results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1","volume":"76","author":"Mease","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","article-title":"Efficacy and safety of the anti-IL-12\/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/annrheumdis-2012-202641","article-title":"Effect of tumour necrosis factor blockers on radiographic progression of psoriatic arthritis: A systematic review and meta-analysis of randomised controlled trials","volume":"73","author":"Goulabchand","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1093\/rheumatology\/keaa313","article-title":"Effect of biologics on radiographic progression of peripheral joint in patients with psoriatic arthritis: Meta-analysis","volume":"59","author":"Wu","year":"2020","journal-title":"Rheumatology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1093\/rheumatology\/keab119","article-title":"Comparative effectiveness of guselkumab in psoriatic arthritis: Results from systematic literature review and network meta-analysis","volume":"60","author":"Mease","year":"2021","journal-title":"Rheumatology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s11547-019-01001-3","article-title":"Radiographic scoring methods in rheumatoid arthritis and psoriatic arthritis","volume":"124","author":"Salaffi","year":"2019","journal-title":"Radiol. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1177\/1536867X1501500403","article-title":"Network meta-analysis","volume":"15","author":"White","year":"2015","journal-title":"Stata J."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Chen, H.L., Tu, Y.K., Chang, H.M., Lee, T.H., Wu, K.L., Tsai, Y.C., Lee, M.H., Yang, C.J., Hung, J.Y., and Chong, I.W. (2020). Systematic review and network meta-analysis of immune checkpoint inhibitors in combination with chemotherapy as a first-line therapy for extensive-stage small cell carcinoma. Cancers, 12.","DOI":"10.3390\/cancers12123629"},{"key":"ref_36","unstructured":"Higgins, J.P.T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M.J., and Welch, V.A. (2021). Cochrane Handbook for Systematic Reviews of Interventions, John Wiley & Sons. [2nd ed.]."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: An overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13643-017-0473-z","article-title":"Approaches to interpreting and choosing the best treatments in network meta-analyses","volume":"6","author":"Mbuagbaw","year":"2017","journal-title":"Syst. Rev."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"j3932","DOI":"10.1136\/bmj.j3932","article-title":"Multivariate and network meta-analysis of multiple outcomes and multiple treatments: Rationale, concepts, and examples","volume":"358","author":"Riley","year":"2017","journal-title":"BMJ"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/aje\/kwn340","article-title":"More than numbers: The power of graphs in meta-analysis","volume":"169","author":"Bax","year":"2009","journal-title":"Am. J. Epidemiol."},{"key":"ref_41","first-page":"712","article-title":"Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept","volume":"33","author":"Mease","year":"2006","journal-title":"J. Rheumatol."},{"key":"ref_42","first-page":"890","article-title":"Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: Primary results from the randomised, double-blind, phase III FUTURE 5 study","volume":"77","author":"Mease","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.semarthrit.2018.05.011","article-title":"Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study","volume":"48","author":"Araujo","year":"2019","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Boutet, M.-A., Nerviani, A., Gallo Afflitto, G., and Pitzalis, C. (2018). Role of the IL-23\/IL-17 axis in psoriasis and psoriatic arthritis: The clinical importance of its divergence in skin and joints. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19020530"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"672515","DOI":"10.3389\/fphar.2021.672515","article-title":"From bed to bench and back: TNF-alpha, IL-23\/IL-17A, and JAK-dependent inflammation in the pathogenesis of ssoriatic synovitis","volume":"12","author":"Silvagni","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.autrev.2018.11.007","article-title":"Amplifying the concept of psoriatic arthritis: The role of autoimmunity in systemic psoriatic disease","volume":"18","author":"Chimenti","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1136\/adc.2007.127316","article-title":"How much loss to follow-up is acceptable in long-term randomised trials and prospective studies?","volume":"93","author":"Fewtrell","year":"2008","journal-title":"Arch. Dis. Child."},{"key":"ref_48","unstructured":"Sch\u00fcnemann, H., Bro\u017cek, J., Guyatt, G., and Oxman, A. (2013). GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations, The GRADE Working Group."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nrrheum.2017.188","article-title":"Enthesitis: From pathophysiology to treatment","volume":"13","author":"Schett","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1002\/acr.23189","article-title":"Radiographic scoring instruments have moderate sensitivity but high specificity for detecting change in axial psoriatic arthritis","volume":"69","author":"Ibrahim","year":"2017","journal-title":"Arthritis Care Res."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/10\/2140\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:48:13Z","timestamp":1760143693000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/10\/2140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,8]]},"references-count":50,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["pharmaceutics14102140"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics14102140","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,8]]}}}